October 17, 2017 Lab Top-10 Life Science Tools PR/Corporate

Thermo Fisher Scientific Customers to Showcase Innovations in Precision Genomics Research for Inherited Disease and Reproductive Health at ASHG

Thermo Fisher Scientific Customers to Showcase Innovations in Precision Genomics Research for Inherited Disease and Reproductive Health at ASHG AmpliSeq On Demand NGS Panels nearly tripled to 3,000 genes for investigating inherited disease-causing variants CARLSBAD, Calif. and ORLANDO, Fla., Oct. 17, 2017 /PRNewswire/ — Inherited diseases are genetically passed down from parent to child through abnormalities... Read more

October 16, 2017 Lab Top-10 PR/Corporate

Thermo Fisher Scientific's Oncomine Dx Target Test for Non-Small Cell Lung Cancer Receives Coverage from First Regional Health Plan

Thermo Fisher Scientific’s Oncomine Dx Target Test for Non-Small Cell Lung Cancer Receives Coverage from First Regional Health Plan Coverage of the comprehensive, multi-biomarker test is now available to Regence BlueCross/BlueShield plan members in Oregon, Idaho, Utah and Washington CARLSBAD, Calif., Oct. 16, 2017 /PRNewswire/ — Thermo Fisher Scientific today announced its Oncomine Dx Target Test... Read more

October 16, 2017 Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Basel, 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to date reinforce favourable benefit-risk profile and advance clinical understanding of disease progression Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today... Read more

October 16, 2017 Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Basel, 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to date reinforce favourable benefit-risk profile and advance clinical understanding of disease progression Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today... Read more

October 13, 2017 Cell Analysis Tools PR/Corporate

BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock

ALAMEDA, Calif.–(BUSINESS WIRE)–Oct. 13, 2017– BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $2.60 per share. The gross proceeds to BioTime from this offering... Read more

October 13, 2017 PR/Corporate

Honeywell Names Brian S. Cook Global Head of M&A

October 13, 2017 MORRIS PLAINS, N.J., Oct. 13, 2017 /PRNewswire/ — Honeywell (NYSE: HON) today named Brian S. Cook as Vice President of Corporate Development and Global Head of Mergers & Acquisitions, reporting to Senior Vice President and CFO Thomas A. Szlosek. Cook succeeds Anne Madden, who was recently named as Honeywell’s Senior Vice President and General Counsel. “Brian has been responsible for... Read more

October 12, 2017 Cell Analysis Tools PR/Corporate

BioTime, Inc. Announces Proposed Public Offering of Common Stock

ALAMEDA, Calif.–(BUSINESS WIRE)–Oct. 12, 2017– BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. BioTime intends to grant the underwriters a 30-day option to purchase up to... Read more

October 12, 2017 Bio/Pharma/CRO Cell Analysis Tools PR/Corporate

BioTime, Inc. Announces Proposed Public Offering of Common Stock

ALAMEDA, Calif.–(BUSINESS WIRE)–Oct. 12, 2017– BioTime, Inc. (“BioTime”) (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. BioTime intends to grant the underwriters a 30-day option to purchase up to... Read more

October 11, 2017 Lab Furniture PR/Corporate

Kewaunee Scientific Reports Board of Directors Join NACD

Exchange: NASDAQ (KEQU) Contact: Thomas D. Hull III 704/871-3290 STATESVILLE, N.C. October 11, 2017 – PRNewswire /Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that its Board of Directors have become members of the National Association of Corporate Directors (“NACD”). The NACD states their vision is to aspire to a world where businesses are sustainable, profitable,... Read more

October 10, 2017 Life Science Tools PR/Corporate

SomaGenics Awarded NIH Funding to Develop NGS Single-Cell Analysis of Small RNAs

SANTA CRUZ, Calif., Oct. 10, 2017 /PRNewswire/ — SomaGenics announced the receipt of a Phase I SBIR grant from the NIH to develop RealSeq®-SC (Single Cell), expected to be the first commercially available library preparation kit for profiling small RNAs (including microRNAs) from single cells using NGS methods. The NIH’s recent Single Cell Analysis Program highlights the... Read more